Exelixis, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Exelixis, Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Exelixis, Inc. and its competitors. This provides our Clients with a clear understanding of Exelixis, Inc. position in the Pharmaceuticals and Biotechnology Industry.

Scope

• The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
• The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
• It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
• Company’s financial ratios are directly compared with those of its competitors through industry averages.
• The report provides relevant news, an analysis of PR-activity, and stock price movements.
• The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.

The benefits of buying the Report are as follows:

• Readers will gain an unrivalled in-depth knowledge about the company.
• The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
• Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• The report will help you to find prospective partners and suppliers.
• The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.

About Exelixis, Inc.

Exelixis, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of cancer and other serious diseases.

Pipeline

The company has a pipeline of compounds in various stages of development that would potentially treat cancer and various metabolic, cardiovascular, and inflammatory disorders. It is focusing its development efforts on its primary clinical compounds, XL184, XL147, and XL765.

XL184

XL184 (BMS-907351), the company’s advanced drug candidate, inhibits MET, VEGFR2 and RET, which are key drivers of tumor growth and/or vascularization. This compound has demonstrated dose-dependent tumor growth inhibition and tumor regression in various preclinical tumor models, including thyroid, breast, pancreatic, non-small cell lung cancer, and glioblastoma. A global phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer is enrolling. The company is planning to initiate a phase 3 registration trial of XL184 as a potential treatment for recurrent glioblastoma. The company has entered into a worldwide co-development collaboration with Bristol-Myers Squibb for the development and commercialization of XL184.

PI3K Inhibitors (XL147 and XL765)

The company is also actively pursuing the development of XL147 and XL765, inhibitors of phosphoinositide-3 kinase (PI3K). XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR. The company is conducting the majority of the clinical trials for these compounds. XL147 and XL765 are being evaluated in a series of phase 1b/2 clinical trials for various solid tumor indications and a phase 2 clinical trial program that commenced in early 2010. In May 2009, the company entered into a global license agreement and discovery collaboration with sanofi-aventis for the development and commercialization of XL147 and XL765 and the discovery of inhibitors of PI3K for the treatment of cancer. While XL147 and XL765 are out-licensed, the company is involved in their development.

Other Compounds

XL139: XL139 (BMS-833923) inhibits activation of Hedgehog (Hh) signaling by binding to smoothened, a key component of the signaling pathway. In preclinical models, XL139 potently inhibits Hh signaling in tumors and significantly slows tumor growth. Additional studies initiated in 2009 or early 2010 included a phase 1b study of XL139 with cisplatin and capecitabine in inoperable, metastatic gastric, gastroesophageal, or esophageal adenocarcinomas, and a phase 1 study of XL139 with carboplatin and etoposide followed by XL139 alone in patients with small cell lung cancer. Bristol-Myers Squibb has exercised its option to develop and commercialize XL139, and the company exercised its option to co-develop and co-commercialize XL139.

XL413: XL413 (BMS-863233) is a small molecule inhibitor of the serine-threonine kinase CDC7. The function of CDC7 is required for DNA replication to proceed, and its activity is often upregulated in cancer cells. A phase 1 clinical trial in patients with hematologic cancer was initiated in March 2009, and phase 1 study in patients with advanced and/or metastatic solid tumors was initiated in May 2009. Bristol-Myers Squibb has exercised its option to develop and commercialize XL413, and the company exercised its option to co-develop and co-commercialize XL413.

XL888: XL888 is a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of key regulatory proteins including kinases. The activity of HSP90 is particularly prominent in tumor cells, where it promotes the activity of proteins controlling cell proliferation and survival. The company has initiated a phase 1 clinical trial.

XL499: XL499 is a potent and selective inhibitor of PI3K-d, a class 1A PI3K isoform expressed primarily in hematopoietic cells and hematologic malignancies. PI3K-d plays important roles in various aspects of immune cell function, including mast cell degranulation, B lymphocyte maturation, and T lymphocyte differentiation. XL499 exhibits potent activity against PI3K-d in cells. XL499 was advanced to development candidate status in January 2010.

O

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. EXELIXIS, INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. EXELIXIS, INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. EXELIXIS, INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. EXELIXIS, INC. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. EXELIXIS, INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Exelixis, Inc. Direct Competitors
5.2. Comparison of Exelixis, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Exelixis, Inc. and Direct Competitors Stock Charts
5.4. Exelixis, Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Exelixis, Inc. Industry Position Analysis

6. EXELIXIS, INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. EXELIXIS, INC. EXPERTS REVIEW

7.1. Experts Opinion
7.2. Experts Estimates

APPENDIX 1: RATIO DEFINITIONS

LIST OF TABLES

Table 1. Exelixis, Inc. Key Facts
Table 2. Exelixis, Inc. Profitability
Table 3. Exelixis, Inc. Management Effectiveness
Table 4. Exelixis, Inc. Income Statement Key Figures
Table 5. Exelixis, Inc. Balance Sheet Key Figures
Table 6. Exelixis, Inc. Cash Flow Statement Key Figures
Table 7. Financial Performance Abbreviation Guide
Table 8. Exelixis, Inc. Key Executives
Table 9. Exelixis, Inc. Key Executives Biographies *
Table 10. Exelixis, Inc. Key Executives Compensations *
Table 11. Exelixis, Inc. Key Executives Stock Options *
Table 12. Exelixis, Inc. Major Shareholders
Table 13. Exelixis, Inc. History
Table 14. Exelixis, Inc. Products
Table 15. Exelixis, Inc. Revenues by Product
Table 16. Exelixis, Inc. Revenues by Region
Table 17. Exelixis, Inc. Offices and Representations
Table 18. Exelixis, Inc. SWOT Analysis
Table 19. Exelixis, Inc. Income Statement 2008-2011 Including 4-years Trends
Table 20. Exelixis, Inc. Income Statement Latest 4 Quarters Including Trends
Table 21. Exelixis, Inc. Balance Sheet 2008-2011 Including Trends
Table 22. Exelixis, Inc. Balance Sheet Latest 4 Quarters Including Trends
Table 23. Exelixis, Inc. Cash Flow 2008-2011 Including Trends
Table 24. Exelixis, Inc. Cash Flow Latest 4 Quarters Including Trends
Table 25. Exelixis, Inc. Profitability Ratios
Table 26. Exelixis, Inc. Margin Analysis Ratios
Table 27. Exelixis, Inc. Asset Turnover Ratios
Table 28. Exelixis, Inc. Credit Ratios
Table 29. Exelixis, Inc. Long-Term Solvency Ratios
Table 30. Exelixis, Inc. Financial Ratios Growth Over Prior Year
Table 31. Exelixis, Inc. Capital Market Snapshot
Table 32. Exelixis, Inc. Direct Competitors Key Facts
Table 33. Exelixis, Inc. Direct Competitors Profitability Ratios
Table 34. Exelixis, Inc. Direct Competitors Margin Analysis Ratios
Table 35. Exelixis, Inc. Direct Competitors Asset Turnover Ratios
Table 36. Exelixis, Inc. Direct Competitors Credit Ratios
Table 37. Exelixis, Inc. Direct Competitors Long-Term Solvency Ratios
Table 38. Pharmaceuticals and Biotechnology Industry Statistics
Table 39. Exelixis, Inc. Industry Position
Table 40. Exelixis, Inc. vs. Industry Income Statement Analysis
Table 41. Exelixis, Inc. vs. Industry Balance Sheet Analysis
Table 42. Exelixis, Inc. vs. Industry Cash Flow Analysis
Table 43. Exelixis, Inc. vs. Industry Ratios Comparison
Table 44. Exelixis, Inc. Consensus Recommendations*
Table 45. Exelixis, Inc. Analyst Recommendation Summary*
Table 46. Exelixis, Inc. Price Target Summary*
Table 47. Exelixis, Inc. Experts Recommendation Trends*
Table 48. Exelixis, Inc. Revenue Estimates Analysis*
Table 49. Exelixis, Inc. Earnings Estimates Analysis*
Table 50. Exelixis, Inc. Historical Surprises*
Table 51. Exelixis, Inc. Revenue Estimates Trend*
Table 52. Exelixis, Inc. Earnings Estimates Trend*
Table 53. Exelixis, Inc. Revenue Revisions*
Table 54. Exelixis, Inc. Earnings Revisions*

LIST OF FIGURES

Figure 1. Exelixis, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Figure 2. Exelixis, Inc. Profit Margin Chart
Figure 3. Exelixis, Inc. Operating Margin Chart
Figure 4. Exelixis, Inc. Return on Equity (ROE) Chart
Figure 5. Exelixis, Inc. Return on Assets (ROA) Chart
Figure 6. Exelixis, Inc. Debt to Equity Chart
Figure 7. Exelixis, Inc. Current Ratio Chart
Figure 8. Exelixis, Inc. 1-year Stock Charts
Figure 9. Exelixis, Inc. 5-year Stock Charts
Figure 10. Exelixis, Inc. vs. Main Indexes 1-year Stock Chart
Figure 11. Exelixis, Inc. vs. Direct Competitors 1-year Stock Charts
Figure 12. Exelixis, Inc. Article Density Chart

* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.

The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.